IBRX Stock Forecast: Biotech Binary Bet 2026
IBRX stock forecast analyzes ImmunityBio’s cancer vaccine potential. Review IBRX stock price, earnings, technicals, and valuation for high-risk biotech plays Introduction ImmunityBio develops T-cell therapies for cancer and infectious diseases. Its lead asset Anktiva targets bladder cancer with NKTR-255 cytokine platform. Investors watch IBRX stock closely now awaiting FDA decisions and Phase 3 readouts. Biotech … Read more